We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant

5 hedge funds and large institutions have $109K invested in NeuroSense Therapeutics Warrant in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 45 (+1)

4.12% more ownership

Funds ownership: 0%4.12% (+4.1%)

52% less capital invested

Capital invested by funds: $229K → $109K (-$120K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
2
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
1
Empery Asset Management
New York
$47K
Hudson Bay Capital Management
2
Hudson Bay Capital Management
Connecticut
$32K
WAM
3
Warberg Asset Management
Illinois
$19K +$1.24K +4,800 +6%
CS
4
Clear Street
New York
$11K +$1.04K +4,045 +8%
UBS Group
5
UBS Group
Switzerland
+$506 +1,958 New

NRSNW Hedge Fund Activity: Q3 2022 in Review

5 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q3 2022, worth a combined $109K — down 52% from $229K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Warberg Asset Management, adding an estimated $1.24K.

  • 5 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q3 2022, up from 4 in Q2 2022.
  • Funds reported $109K of NeuroSense Therapeutics Warrant stock for Q3 2022, down 52% quarter-over-quarter.
  • 1 fund opened new NeuroSense Therapeutics Warrant positions in Q3 2022 and 0 closed out, a net change of +1 holder.
  • The largest NeuroSense Therapeutics Warrant buyer in Q3 2022 was Warberg Asset Management, an estimated $1.24K added.

Based on aggregated 13F filings for Q3 2022.